CTX001 for transfusion-dependent beta-thalassemia (TDT): safety and efficacy results from the ongoing CLIMB THAL-111 study of autologous CRISPR-CAS9-modified CD34(+) hematopoietic stem and progenitor cells (HSPCs)
HAEMATOLOGICA（2021）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要